According to SNS Insider, the DNA Manufacturing Market was valued at USD 5.18 billion in 2024 and is projected to reach USD 20.28 billion by 2032, growing at a compound annual growth rate (CAGR) of 18 ...
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game changer. The FDA no longer agrees that data ...
Gene and his wife, Betsy's estate have been hit with a slew of creditor claims GENE Hackman and wife, Betsy Arakawa, were sued after their death for a nearly $2,000 bill from a phone company. The U.S.
GENE Hackman and wife, Betsy Arakawa, were sued after their death for a nearly $2,000 bill from a phone company. The U.S. Sun exclusively obtained documents filed against the Hackmans’ estate on ...
Gene Hackman's deeply personal art collection and awards head to auction, months after actor’s death
A trove of Gene Hackman's personal artworks and awards will be brought to auction in November, nine months after the late actor's death. Bonhams international auction house secured more than 400 items ...
The company took to the social media platform X on Wednesday to commemorate the occasion. "Congratulations to the Giga Texas team for building 500k vehicles," the post said. The Gigafactory recently ...
A DUI CRASH. THE GIRL’S MOTHER AND FOUR-YEAR-OLD SISTER ARE STILL IN THE HOSPITAL TONIGHT. WLKY’S JAMIE MAYES JOINS US NOW LIVE OUTSIDE OF NORTON CHILDREN’S, WHERE THE FAMILY IS STRUGGLING WITH THE ...
The Impala was already America's number one nameplate in 1962, and Chevrolet knew this well. The company used the 1962 model year to pay more attention to other models, such as the Chevy II and the ...
Fifty years ago, a Texas-born country singer had his first big hit: a tune named “Love in the Hot Afternoon.” It reached the third spot on the Billboard country chart. “That song is still so popular,” ...
Fifty years ago, a Texas-born country singer had his first big hit: a tune named “Love in the Hot Afternoon.” It reached the third spot on the Billboard country chart. “That song is still so popular,” ...
Sarepta Therapeutics' controversial gene therapy, Elevidys, has received another regulatory blow. The biopharmaceutical company on Friday said that the Committee for Medicinal Products for Human Use ...
Ultragenyx is going through a rough patch. Days after reporting a disappointing mid-term phase 3 readout for an antibody drug, the company has received an FDA rejection for its rare disease gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback